Area of research
Hepatology · Epidemiology
Research interest
Research interests include Hepatocellular Carcinoma Treatment and Prognosis, Liver Disease Diagnosis and Treatment, Liver Disease and Transplantation, and Cancer Genomics and Diagnostics.
Unraveling the tapestry: Lessons from multi-omics and spatial biology in hepatocellular cancer.
Risk Factors for Primary Sclerosing Cholangitis Recurrence Following Liver Transplantation: A Multicenter Retrospective Analysis.
A Novel Niclosamide Sulfate Prodrug with Enhanced Bioavailability Suppresses Hepatocellular Carcinoma via Inhibition of Multiple Signaling Pathways
Molecular and immune landscape of hepatocellular carcinoma to guide therapeutic decision-making.
The Immune Microenvironment of Transplant Glomerulitis
The Immune Microenvironment of Transplant Glomerulitis.
Redefining cancer care: the case for an onco-gastroenterology subspecialty.
Author Correction: Matrix viscoelasticity promotes liver cancer progression in the pre-cirrhotic liver.
Supplementary Figures from MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages
Supplementary Tables from MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages
Matrix viscoelasticity promotes liver cancer progression in the pre-cirrhotic liver.
Battle of the biopsies: Role of tissue and liquid biopsy in hepatocellular carcinoma.
Spatial analysis reveals targetable macrophage-mediated mechanisms of immune evasion in hepatocellular carcinoma minimal residual disease.
Nuclear to cytoplasmic transport is a druggable dependency in MYC-driven hepatocellular carcinoma
Nuclear to cytoplasmic transport is a druggable dependency in MYC-driven hepatocellular carcinoma.
Practical approach to diagnose and manage benign liver masses.
MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint
MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint.
MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages.
Downstaging hepatocellular carcinoma before liver transplantation: A multicenter analysis of the “all-comers” protocol in the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) consortium
Downstaging hepatocellular carcinoma before liver transplantation: A multicenter analysis of the "all-comers" protocol in the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) consortium.
Long-term clinical outcomes of patients with COVID-19 and chronic liver disease: US multicenter COLD study.
Supplementary Figures from MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages
Supplementary Tables from MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages
Data from MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages
Supplementary Figures from MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages
Supplementary Tables from MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages
Data from MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages
The MYC oncogene - the grand orchestrator of cancer growth and immune evasion.
Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis.